BioTools Innovator VANGUARD is at the forefront of innovation for enabling life science technologies. VANGUARD supports biotools startups to develop solutions that improve drug discovery and development; to increase biomanufacturing speed, capacity, portability, and scalability; to enhance sample processing efficiency and diagnostic assay capabilities; and to accelerate bioanalysis of emerging pathogens. VANGUARD stands ready to support startups in deploying innovative medical countermeasures that enhance the United States’ readiness for public health emergencies.
VANGUARD is a joint initiative between BioTools Innovator, the world’s first-ever accelerator focused on life science research tools, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
Through Level UP-XR: Training for Biopharmaceutical Manufacturing Technicians, BioTools Innovator VANGUARD will provide non-dilutive funding to innovative CDMO and XR companies creating next-generation training solutions that strengthen the biopharmaceutical manufacturing workforce.
Learn More >
Through ReadyDetect: Blood Sampling Competition, BioTools Innovator VANGUARD will award over $5M in prizes to companies advancing next-generation capillary blood collection and processing devices for diagnostics at the point of need — home, field, and resource-limited settings.
Learn More >
Three CDMO–XR Company Pairs to Receive Up to $300,000 Each to Pilot GMP Technician Training…
—BioTools Innovator VANGUARD supports development & validation projects of 5 startups through non-dilutive funding awards.—…
A new prize competition seeks innovative blood collection and sample preparation technologies to expand access…
Los Angeles - December 2, 2025 - BioTools Innovator (BTI) VANGUARD, in partnership with the…
The BARDA Accelerator Network aims to provide comprehensive support to health security innovators, startups and BARDA portfolio companies through wrap-around accelerator services, technical and business/commercialization expertise, and resources. The network will facilitate the rapid development, evaluation, validation and commercialization of medical countermeasures.
Learn more at the BARDA Accelerator Network.
The BARDA Accelerator Network, made up of five Hubs, is built to drive growth in the startup ecosystem by speeding up the creation and market entry of cutting-edge health security solutions. Each Hub sources promising early-stage innovations within their specialized technology areas and offers funding to evaluate the feasibility of these concepts and provides resources for commercialization, helping to fast-track product development and validation.
BioTools Innovator VANGUARD is at the forefront of biomanufacturing innovation, enabling life science tools startups to develop solutions that improve drug discovery and development; increase speed, capacity, portability, and scalability; and improve clinical research and clinical care coordination.
The International Consortium for Research, Engineering, Acceleration of Technology Excellence (I-CREATE) Hub supports the development and acceleration of novel diagnostics and medical devices to detect, prevent, or respond to medical consequences that result from health security threats.
Focus on innovations that can improve the detection, diagnosis, treatment, and informed outcomes in pediatric/neonatal populations and immunocompromised populations to enable health equity solutions in traditionally underrepresented communities and low-resource settings.
The Vaccine Innovations and Therapeutics Acceleration Launchpad (VITAL) Hub will support the development and acceleration of next-generation therapeutic and vaccine platforms and technologies.
BioTools Innovator VANGUARD is at the forefront of biomanufacturing innovation, enabling life science tools startups to develop solutions that improve drug discovery and development; increase speed, capacity, portability, and scalability; and improve clinical research and clinical care coordination.
The International Consortium for Research, Engineering, Acceleration of Technology Excellence (I-CREATE) Hub supports the development and acceleration of novel diagnostics and medical devices to detect, prevent, or respond to medical consequences that result from health security threats.
Focus on innovations that can improve the detection, diagnosis, treatment, and informed outcomes in pediatric/neonatal populations and immunocompromised populations to enable health equity solutions in traditionally underrepresented communities and low-resource settings.
The Vaccine Innovations and Therapeutics Acceleration Launchpad (VITAL) Hub will support the development and acceleration of next-generation therapeutic and vaccine platforms and technologies.
For additional information and questions, please contact vanguard@biotoolsinnovator.org.
